Elanco Animal Health Incorporated

Elanco Animal Health Incorporated

ELANยทNYSE

$24.58

+3.9%
HealthcareDrug Manufacturers - Specialty & Generic

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

At a Glance

Live Snapshot
Market Cap$12.28B
EPS-0.4700
P/E Ratio-52.30
Earnings Date08/06/2026
3Y+24.0%
5Y-1466.0%
10Y+259.0%
3Y+56.0%
5Y-94.0%
10Y+53.0%
3Y-50.0%
5Y-106.0%
10Y+84.0%
ELAN

Elanco Animal Health Incorporated Cash Conversion Engine

ELAN ยท NYSE
Net Income-232.00M
Depreciation & Amortization680.00M
Stock-Based Compensation68.00M
Change in Working Capital99.00M
Others79.00M
Capital Expenditures-276.00M
Free Cash Flow284.00M

Cash Flow Quality Analysis

FCF Conversion Rate

-122.4%

Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.

CapEx Intensity

49.3%

Capital-intensive operations require significant reinvestment. Monitor whether CapEx is maintenance or growth-oriented.

FCF Growth Trend

-27.9%

Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.

Working Capital Impact

+$99.00M

Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.

Cash Flow Quality Insight

Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.

Elanco Animal Health Incorporated Cash Flow Statement

ELAN โ€ข NYSE

Elanco Animal Health Incorporated Cash Flow StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
OPERATING ACTIVITIES
-232M
338M
-1.2B
-78M
-472M
-574M
67.9M
86.5M
-310.7M
-47.9M
-210.8M
680M
662M
694M
682M
716M
517M
314.5M
296M
318.4M
254.4M
236.9M
-134M
-112M
-80M
-57M
-154M
-114M
100K
-60.7M
-13.4M
-5.9M
-76.2M
68M
55M
46M
59M
66M
47M
49.4M
26M
25M
20.4M
13.4M
79M
-551M
1.1B
308M
414M
-86M
19.9M
168.7M
101M
104.3M
59M
99M
149M
-300M
-462M
-87M
169M
-227.7M
-29.2M
53.5M
-169.4M
-15.7M
560M
541M
271M
452M
483M
-41M
224.1M
487.3M
173.8M
155.9M
6.6M
INVESTING ACTIVITIES
-276M
-147M
-140M
-184M
-197M
-310.9M
-197.4M
-134.5M
-98.6M
-110.3M
-100.1M
(0.0)
(1.3B)
-19M
(13M)
-342M
-4.6B
-32.8M
(9.4M)
-882.1M
-45M
-5.3B
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
-103.6M
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
0.0
0.0
0.0
0.0
0.0
32.7M
0.0
0.0
0.0
0.0
0.0
-3M
-14M
-10M
-8M
9M
169.2M
-4.6M
-1.9M
16.1M
-26.8M
387.8M
-279M
(1.2B)
-169M
-179M
-530M
-4.8B
-234.8M
-127M
-964.6M
-182.1M
-5B
FINANCING ACTIVITIES
0.0
0.0
0.0
0.0
0.0
1.2B
0.0
1.7B
0.0
0.0
0.0
-563M
-1.5B
-77M
-517M
177M
3.9B
-121M
2.5B
0.0
0.0
0.0
288M
-17M
-6M
-32M
33M
-118.1M
-183.8M
-4.2B
847.5M
-149.6M
5.4B
-275M
-1.5B
-83M
-549M
210M
5B
-304.8M
-35.2M
847.5M
-149.6M
5.4B
CASH FLOW SUMMARY
71M
-91M
-12M
-17M
-31M
26.6M
-16.9M
29M
7.9M
-26M
-19.8M
77M
116M
7M
-293M
132M
160.3M
-332.4M
354.1M
64.6M
-201.8M
344.6M
468M
352M
345M
638M
506M
345.1M
677.5M
323.4M
258.8M
460.6M
116M
545M
468M
352M
345M
638M
505.4M
345.1M
677.5M
323.4M
258.8M
460.6M
284M
394M
117M
268M
286M
-351.9M
26.7M
352.8M
75.2M
45.6M
-93.5M

SEC Filings

ELAN - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 27, 2026
May 21, 2026
2026
10-Q

10-Q 2026 Q1

Q1

May 06, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

May 06, 2026
May 06, 2026
2026
DEF 14A

DEF 14A 2025

N/A

April 08, 2026
December 31, 2025
2025
10-K

10-K 2025 FY

FY

February 24, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 24, 2026
February 24, 2026
2026
8-K

8-K 2026

N/A

January 12, 2026
January 12, 2026
2026
8-K

8-K 2025

N/A

December 09, 2025
December 05, 2025
2025
8-K

8-K 2025

N/A

November 05, 2025
November 05, 2025
2025
10-Q

10-Q 2025 Q3

Q3

November 05, 2025
September 30, 2025
2025
Showing 1 to 10 of 164 filings